Table 1 Population characteristics of TVD patients who received follow-up CAG after second-generation DES implantation

Age (years)

64.3 ± 10.0

63.8 ± 9.9

65.0 ± 10.0

0.340

67.3 ± 10.2

63.6 ± 9.8

0.029•

Male (n, %)

174 (70.7%)

101 (71.1%)

73 (70.2%)

0.874

31 (72.1%)

143 (70.4%)

0.829

BMI (kg/m²)

26.2 ± 3.3

26.2 ± 3.4

26.2 ± 3.2

0.948

26.1 ± 2.9

26.2 ± 3.3

0.858

Current smoking (n, %)

92 (37.4%)

66 (46.5%)

26 (25.0%)

0.001*

22 (51.2%)

70 (34.5%)

0.040•

Current alcohol intake (n, %)

66 (26.8%)

41 (28.9%)

25 (24.0%)

0.398

10 (23.3%)

56 (27.6%)

0.560

Hypertension (n, %)

186 (75.6%)

112 (78.9%)

74 (71.2%)

0.164

32 (74.4%)

154 (75.9%)

0.841

SBP > 140 and/or DBP > 90 (n, %)

70 (29.3%)

38 (26.8%)

34 (32.4%)

0.312

10 (23.3%)

62 (30.5%)

0.340

Diabetes (n, %)

129 (52.4%)

81 (57.0%)

48 (46.2%)

0.091

24 (55.8%)

105 (51.7%)

0.626

Family history of CAD (n, %)

76 (30.9%)

45 (31.7%)

31 (29.8%)

0.752

12 (27.9%)

64 (31.5%)

0.641

CKD1-3 (n, %)

20 (8.1%)

13 (9.2%)

7 (6.7%)

0.492

5 (11.6%)

15 (7.4%)

0.356

CKD4-5 (n, %)

9 (3.7%)

9 (6.3%)

0

/

4 (9.3%)

5 (2.5%)

0.030•

Angina pectoris or precordial distress (n, %)

202 (82.1%)

136 (95.8%)

66 (63.5%)

 < 0.001*

38 (88.4%)

164 (80.8%)

0.238

Laboratory test

TC (mmol/L)

3.63 ± 0.84

3.76 ± 0.90

3.44 ± 0.74

0.005*

3.84 ± 1.04

3.58 ± 0.79

0.073

LDL-C (mmol/L)

1.95 ± 0.63

2.07 ± 0.69

1.79 ± 0.51

0.001*

2.00 ± 0.75

1.94 ± 0.61

0.552

HDL-C (mmol/L)

1.00 ± 0.24

0.97 ± 0.22

1.05 ± 0.26

0.004*

1.01 ± 0.30

0.99 ± 0.23

0.674

Non-HDL-C (mmol/L)

2.63 ± 0.81

2.80 ± 0.75

2.40 ± 0.66

 < 0.001*

2.83 ± 1.05

2.59 ± 0.75

0.083

ApoB (g/L)

0.74 ± 0.20

0.77 ± 0.20

0.70 ± 0.18

0.009*

0.74 ± 0.19

0.74 ± 0.20

0.788

NEU (× 10⁹)

4.39 ± 1.40

4.59 ± 1.48

4.11 ± 1.23

0.008*

4.72 ± 1.46

4.31 ± 1.38

0.078

LY (× 10⁹)

1.82 ± 0.69

1.80 ± 0.66

1.82 ± 0.73

0.874

1.80 ± 0.65

1.81 ± 0.70

0.923

NLR

2.40 (1.88, 3.08)

2.43 (1.91, 3.29)

2.26 (1.81, 2.86)

0.120

2.50 (2.11, 3.58)

2.39 (1.86, 3.05)

0.179

WBC (× 10⁹)

6.82 ± 1.82

7.04 ± 1.83

6.52 ± 1.79

0.672

7.15 ± 1.95

6.74 ± 1.80

0.184

Hs-CRP (mg/L)

0.96 (0.43, 2.22)

1.22 (0.53, 2.68)

0.83 (0.39, 1.88)

0.022*

1.38 (0.70, 3.23)

0.92 (0.40, 2.15)

0.066

HbA1c (%)

6.3 (5.8, 7.3)

6.4 (5.8, 7.8)

6.2 (5.8, 6.8)

0.090

6.4 (6.0, 8.4)

6.2 (5.8, 7.1)

0.050

SUA (μmol/L)

351 (296, 403)

357(297, 409)

339 ± 78

0.320

341 (289, 401)

354 (299, 405)

0.680

Previous findings

ACS (n/%)

154 (62.6%)

88 (62.0%)

66 (63.5)

0.811

19 (44.2%)

73 (36.0%)

0.311

Target vessel at LM (n/%)

22 (8.9%)

9 (5.3%)

13 (12.5%)

0.094

2 (4.7%)

20 (9.9%)

0.278

Target vessel at LAD only (n/%)

63 (25.6%)

36 (25.4%)

27 (26.0%)

0.914

14 (32.6%)

49 (24.1%)

0.250

Target vessel at LCX only (n/%)

29 (11.8%)

18 (12.7%)

11(10.6%)

0.614

0 (0%)

29 (4.3%)

/

Target vessel at RCA only (n/%)

45 (18.3%)

26 (18.3%)

19 (18.3%)

0.994

6 (14.0%)

39 (19.2%)

0.418

Two vessels stenting (n/%)

93 (37.8%)

53 (37.3%)

40 (38.5%)

0.856

18 (41.9%)

75 (36.9%)

0.546

Triple vessels stenting (n/%)

17 (6.9%)

10 (7.0%)

7 (6.7%)

0.924

5 (11.6%)

12 (5.9%)

0.179

SYNTAX score

12.9 ± 4.5

13.4 ± 4.7

12.4 ± 4.0

0.085

12.6 ± 5.3

13.0 ± 4.3

0.558

Everolimus/zotarolimus-eluting stents (n/%)

184 (74.8%)

107 (75.4%)

77 (74.0%)

0.815

31 (72.3%)

153 (75.4%)

0.653

Time of follow-up (months)

28.0 (14.0,56.0)

16.8 (38.0,63.0)

23.5 (13.0,48.5)

0.002*

39.0 (22.0,78.0)

27.0 (14.0, 53.0)

0.024•